GCM
EWTX icon

Graham Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Graham Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,468
Closed -$235K – 1273
2025
Q4 		$235K Sell
9,468
-9,321
-50% -$187K 0.01% 967
2025
Q3 		$305K Sell
18,789
-21,575
-53% -$306K ﹤0.01% 847
2025
Q2 		$529K Buy
40,364
+23,317
+137% +$336K 0.01% 791
2025
Q1 		$375K Sell
17,047
-1,368
-7% -$35.9K 0.01% 913
2024
Q4 		$492K Buy
18,415
+2,516
+16% +$80.1K 0.01% 743
2024
Q3 		$424K Sell
15,899
-18,612
-54% -$370K 0.01% 681
2024
Q2 		$622K Buy
34,511
+7,669
+29% +$134K 0.01% 518
2024
Q1 		$490K Buy
+26,842
New +$427K 0.01% 635
2022
Q4 		– Sell
-40,494
Closed -$398K – 1113
2022
Q3 		$398K Buy
+40,494
New +$409K 0.02% 813

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Graham Capital Management's EWTX Position: Q1 2026 in Review

Graham Capital Management sold out of Edgewise Therapeutics (EWTX) in Q1 2026, closing a stake of 9,468 shares — an estimated $235K sold.

Graham Capital Management first reported a position in EWTX in Q3 2022 and held it in 9 quarters. The position peaked at $622K in Q2 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Graham Capital Management reported no remaining Edgewise Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 9,468 Edgewise Therapeutics shares in Q1 2026, an estimated $235K.
  • Graham Capital Management first reported a position in Edgewise Therapeutics in Q3 2022 and held it in 9 quarters.
  • Graham Capital Management's Edgewise Therapeutics position peaked at $622K in Q2 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.